Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.80 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | RET | P07949 | 1/20 | 0.73 |
| ▸ | KDR | P35968 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | GABRP | O00591 | 1/20 | 0.62 |
| ▸ | GABRD | O14764 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29494586 | 1.00 | PPARG (0.80) | PPARGEGFRRETKDRMAPT | |
| SCHEMBL4839605 | 0.88 | PLG (0.67) | PPARGMAPTABCB1ABCG2CYP3A4 | |
| SCHEMBL4056341 | 0.86 | MAPT (0.72) | PPARGEGFRRETKDRMAPT | |
| SCHEMBL8391032 | 0.83 | EGFR (0.74) | EGFRRETKDRMAPTABCB1 | |
| SCHEMBL24882669 | 0.82 | EGFR (0.78) | PPARGEGFRRETKDRMAPT | |
| SCHEMBL10025658 | 0.82 | MAPT (0.77) | PPARGEGFRRETKDRMAPT | |
| SCHEMBL30376285 | 0.82 | MAPT (1.00) | PPARGEGFRRETKDRMAPT | |
| SCHEMBL974548 | 0.82 | MAPT (1.00) | PPARGEGFRRETKDRMAPT | |
| SCHEMBL12678185 | 0.81 | EGFR (0.80) | EGFRRETKDRMAPTABCB1 | |
| SCHEMBL22729259 | 0.81 | MAPT (0.81) | PPARGEGFRRETKDRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210038562-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPLICATIONS COMPRISING NOVEL CHRYSIN DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | FRONTBIO INC. (KR) | 2021-02-11 | — | — | US | disclosed |
| EP-3747435-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPLICATIONS COMPRISING NOVEL CHRYSIN DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | FRONTBIO INC. (KR) | 2020-12-09 | — | — | EP | disclosed |
| EP-3747435-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPLICATIONS COMPRISING NOVEL CHRYSIN DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | FRONTBIO INC. (KR) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019151732-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPLICATIONS COMPRISING NOVEL CHRYSIN DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | 한림대학교 산학협력단 | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038562-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPLICATIONS COMPRISING NOVEL CHRYSIN DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | AGER, IAPP, GCG | PPARG 254/4885EGFR 2350/4885RET 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.